Prescription drug · ANDA
Dihydroergotamine Mesylate NDC 24201-463
Dihydroergotamine mesylate 4 mg/mL · Spray · Nasal · Hikma Pharmaceuticals USA Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 24201-463-08 | 24201046308 | 8 VIAL in 1 CARTON (24201-463-08) / 1 mL in 1 VIALMarketed from Apr 14, 2020 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Dihydroergotamine Mesylate
- Generic name (nonproprietary)
- dihydroergotamine mesylate
- Active ingredients
- Dihydroergotamine mesylate — 4 mg/mL
- Dosage form
- Spray
- Route
- Nasal
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 211393
- Marketing start
- Listing expires
- Other FDA classes
- Ergotamines (Chemical structure)
- Identifiers
- Product ID 24201-463_d9b07b6a-d574-4490-8294-8727e7a004afSPL ID d9b07b6a-d574-4490-8294-8727e7a004afSPL set ID 9ffe6d5a-7348-0498-e053-2a95a90a97a8RxCUI 861668UNII 81AXN7R2QTUPC 0324201463083, 0324201463014
- Pharmacologic class
- Ergotamine Derivative
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Nasal products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N424201046308followed by a unit qualifier and the quantityPackage 24201-0463-08. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE Dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. Dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine.
Excerpt only. Read the full label for complete information.